We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MBB icon
426
iShares MBS ETF
MBB
$39.1B
$1.71M 0.05%
16,107
+4,381
+37% +$465K
LULU icon
427
lululemon athletica
LULU
$13.6B
$1.7M 0.05%
32,308
+23,167
+253% +$1.16M
NIE
428
Virtus Equity & Convertible Income Fund
NIE
$712M
$1.7M 0.05%
87,268
+3,119
+4% +$60.1K
XLK icon
429
State Street Technology Select Sector SPDR ETF
XLK
$115B
$1.69M 0.05%
93,202
-13,904
-13% -$248K
FITB
430
Fifth Third Bancorp
FITB
$51.3B
$1.69M 0.05%
73,512
-11,322
-13% -$247K
PPC icon
431
Pilgrim's Pride
PPC
$6.99B
$1.67M 0.05%
79,937
+11,547
+17% +$199K
AXS icon
432
AXIS Capital
AXS
$7.67B
$1.67M 0.05%
36,400
-300
-0.8% -$13.5K
GATX icon
433
GATX Corp
GATX
$6.45B
$1.67M 0.05%
+24,579
New +$1.48M
IVE icon
434
iShares S&P 500 Value ETF
IVE
$49.1B
$1.64M 0.05%
18,845
-850
-4% -$71.8K
KERX
435
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.64M 0.05%
95,943
-19,524
-17% -$295K
MCI
436
Barings Corporate Investors
MCI
$342M
$1.63M 0.05%
107,683
-200
-0.2% -$3.1K
NSM
437
DELISTED
Nationstar Mortgage Holdings
NSM
$1.62M 0.05%
49,938
+40,318
+419% +$1.24M
SNDK
438
DELISTED
SANDISK CORP
SNDK
$1.62M 0.05%
19,963
-12,998
-39% -$959K
SLV icon
439
iShares Silver Trust
SLV
$28.6B
$1.61M 0.05%
84,832
-964
-1% -$19K
TT icon
440
Trane Technologies
TT
$97.3B
$1.61M 0.05%
28,125
+23,225
+474% +$1.38M
MCK icon
441
McKesson
MCK
$101B
$1.6M 0.05%
9,085
+2,519
+38% +$440K
SPLK
442
DELISTED
Splunk Inc
SPLK
$1.6M 0.05%
+22,442
New +$1.83M
TIP icon
443
iShares TIPS Bond ETF
TIP
$14.5B
$1.59M 0.05%
14,220
+1,979
+16% +$221K
GHDX
444
DELISTED
Genomic Health, Inc.
GHDX
$1.59M 0.05%
60,415
+7,550
+14% +$217K
ALXN
445
DELISTED
Alexion Pharmaceuticals
ALXN
$1.59M 0.05%
10,443
+535
+5% +$85.1K
PDI icon
446
PIMCO Dynamic Income Fund
PDI
$7.44B
$1.59M 0.05%
52,301
+1,679
+3% +$51K
TM icon
447
Toyota
TM
$227B
$1.58M 0.05%
14,015
+2,975
+27% +$343K
VUG icon
448
Vanguard Morningstar Growth ETF
VUG
$218B
$1.58M 0.05%
101,460
-22,020
-18% -$342K
RSE
449
DELISTED
ROUSE PPTYS INC COM (DE)
RSE
$1.58M 0.05%
91,591
+3,476
+4% +$63.3K
CX icon
450
Cemex
CX
$17.2B
$1.56M 0.05%
+144,308
New +$1.56M

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.